List view / Grid view
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
26 September 2013 | By Penn Pharma
A £14 million state-of-the-art facility formally opened...
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
25 September 2013 | By GSK
European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection...
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
25 September 2013 | By AbbVie
Global alliance formed to discover, develop and commercialise novel potentiator and combination therapies in cystic fibrosis...
24 September 2013 | By Janssen Research & Development, LLC
In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo...
24 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that results from two different pooled analyses of clinical studies support previous observations that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin was shown to be well tolerated in a broad range of adults with Type 2 Diabetes (T2D). These data were presented…
24 September 2013 | By Takeda
Authorisation received for VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) and IncresyncTM (alogliptin and pioglitazone)...
24 September 2013 | By Daiichi Sankyo Company, Limited
Ranbaxy Laboratories has received communication from the FDA about an Import Alert imposed on its Mohali, India, plant following an inspection in late 2012...
23 September 2013 | By Cancer Research UK
Dr Simon Boulton has been named as one of the recipients of the 2013 Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center in America...
